KR20240026905A - 림프구의 단일 용기 확장 - Google Patents

림프구의 단일 용기 확장 Download PDF

Info

Publication number
KR20240026905A
KR20240026905A KR1020237041122A KR20237041122A KR20240026905A KR 20240026905 A KR20240026905 A KR 20240026905A KR 1020237041122 A KR1020237041122 A KR 1020237041122A KR 20237041122 A KR20237041122 A KR 20237041122A KR 20240026905 A KR20240026905 A KR 20240026905A
Authority
KR
South Korea
Prior art keywords
cells
lymphocytes
cell
tumor
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237041122A
Other languages
English (en)
Korean (ko)
Inventor
조지 쿠코스
알렉상드르 하라리
시몬 슈타이너
플로렌스 살몬
Original Assignee
티젠 파마 에스에이
루드비히 인스티튜트 포 캔서 리서치 리미티드
쌍트르 오스삐딸리에 위니베르씨떼 보두와 (씨에이치유브이)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 티젠 파마 에스에이, 루드비히 인스티튜트 포 캔서 리서치 리미티드, 쌍트르 오스삐딸리에 위니베르씨떼 보두와 (씨에이치유브이) filed Critical 티젠 파마 에스에이
Publication of KR20240026905A publication Critical patent/KR20240026905A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/98—Xeno-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1107—B cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
KR1020237041122A 2021-04-30 2022-04-29 림프구의 단일 용기 확장 Pending KR20240026905A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21171565.1 2021-04-30
EP21171565 2021-04-30
PCT/EP2022/061639 WO2022229464A1 (en) 2021-04-30 2022-04-29 Single vessel expansion of lymphocytes

Publications (1)

Publication Number Publication Date
KR20240026905A true KR20240026905A (ko) 2024-02-29

Family

ID=76034406

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237041122A Pending KR20240026905A (ko) 2021-04-30 2022-04-29 림프구의 단일 용기 확장

Country Status (10)

Country Link
US (1) US20240287454A1 (https=)
EP (1) EP4330380A1 (https=)
JP (1) JP2024517793A (https=)
KR (1) KR20240026905A (https=)
CN (1) CN117321189A (https=)
AU (1) AU2022267777A1 (https=)
BR (1) BR112023022485A2 (https=)
CA (1) CA3214450A1 (https=)
MX (1) MX2023012698A (https=)
WO (1) WO2022229464A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115558641B (zh) * 2022-11-14 2023-05-12 四川新生命干细胞科技股份有限公司 高纯度效应免疫细胞群及其培养方法、试剂组合物和应用
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
CU23734A1 (es) 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
EP2983702A2 (en) 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
US20160310584A1 (en) 2013-12-06 2016-10-27 The Broad Institute Inc. Formulations for neoplasia vaccines
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
EP3323070B1 (en) 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
CA3034452A1 (en) 2016-08-21 2018-03-01 Adva Biotechnology Ltd. Bioreactor and methods of use thereof
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
EP3707245A1 (en) * 2017-11-06 2020-09-16 Ludwig Institute for Cancer Research Ltd Method for expansion of lymphocytes
US20230052157A1 (en) 2019-12-12 2023-02-16 Achilles Therapeutics Uk Limited Method for obtaining nucleic acid for sequencing
JP2023510950A (ja) 2020-01-20 2023-03-15 アドヴァ バイオテクノロジー リミテッド バイオリアクタを制御する装置及び方法

Also Published As

Publication number Publication date
CA3214450A1 (en) 2022-11-03
JP2024517793A (ja) 2024-04-23
MX2023012698A (es) 2024-02-21
WO2022229464A1 (en) 2022-11-03
BR112023022485A2 (pt) 2024-01-09
US20240287454A1 (en) 2024-08-29
EP4330380A1 (en) 2024-03-06
AU2022267777A1 (en) 2023-10-05
CN117321189A (zh) 2023-12-29

Similar Documents

Publication Publication Date Title
CN113631172B (zh) 用于靶向突变型ras的组合物和方法
KR102809909B1 (ko) P53 암-특이적 돌연변이에 대한 항원 특이성을 갖는 t 세포를 단리하는 방법
TWI752930B (zh) 抗原特異性ｔｃｒ的新生成
TW201928052A (zh) 靶向ny-eso-1的基因修飾免疫細胞及其用途
KR20140135715A (ko) 항종양 활성 및 ｃａｒ 지속을 증진시키기 위한 ｉｃｏｓ 기반 ｃａｒ의 용도
US20210317184A1 (en) T cell modification
KR20190126332A (ko) 암 면역치료요법을 위한 mr1 제한된 t 세포 수용체
CN107106609A (zh) 刺激和扩展t细胞的组合物和方法
US20250186586A1 (en) Methods of isolating and enhancing populations of tumor-reactive lymphocytes
US20250241849A1 (en) Compositions and methods for treating immunological dysfunction
KR20210057750A (ko) 암 면역치료요법을 위한 mr1 제한된 t 세포 수용체
KR20240026905A (ko) 림프구의 단일 용기 확장
WO2023076523A1 (en) Chimeric adaptor polypeptides
KR20250144510A (ko) 림프구 확장
Bilsborough et al. A MAGE‐3 peptide presented by HLA‐B44 is also recognized by cytolytic T lymphocytes on HLA‐B18
CN121127257A (zh) 携带kras结合蛋白并敲除内源性tcr的宿主细胞及其使用方法
KR20230154851A (ko) 확장 및 생체내 보존을 위한 조작된 nkt 세포 및 종양 세포 조절을 위한 사용 방법
CN120210284A (zh) 一种冻存细胞制备表达嵌合抗原受体的细胞的方法
EA041619B1 (ru) Способ продуцирования человеческих антигенспецифических т-лимфоцитов

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231128

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250429

Comment text: Request for Examination of Application